A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy

Urol Oncol. 2015 Jun;33(6):269. doi: 10.1016/j.urolonc.2015.01.026. Epub 2015 Mar 26.
No abstract available

Publication types

  • Editorial
  • Introductory Journal Article

MeSH terms

  • Benchmarking / methods*
  • Biomarkers, Tumor / metabolism*
  • Drug Discovery
  • Humans
  • Medical Oncology
  • Urologic Neoplasms / drug therapy*
  • Urologic Neoplasms / mortality

Substances

  • Biomarkers, Tumor